Page last updated: 2024-12-08

3,3',4'-trihydroxyflavone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3',4'-dihydroxyflavonol: a neuroprotective agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID145826
CHEMBL ID122701
CHEBI ID190992
SCHEMBL ID169366

Synonyms (35)

Synonym
np-202
tnp00069 ,
NCGC00017204-01
NCGC00142445-01
3,3'',4''-trihydroxyflavone
2-(3,4-dihydroxy-phenyl)-3-hydroxy-chromen-4-one
2-(3,4-dihydroxyphenyl)-3-hydroxy-4h-chromen-4-one
3'',4''-dihydroxyflavonol
bdbm50092528
3',4'-dihydroxyflavonol
CHEMBL122701 ,
2-(3,4-dihydroxyphenyl)-3-hydroxychromen-4-one
CHEBI:190992
3,3',4'-trihydroxyflavone
6068-78-6
unii-r1i1r1c88v
2-(3,4-dihydroxyphenyl)-3-hydroxy-4h-1-benzopyran-4-one
r1i1r1c88v ,
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-hydroxy-
NCGC00017204-02
SCHEMBL169366
mfcd00189455
AKOS024282400
diohf
2-(3,4-dihydroxyphenyl)-3-hydroxy-4h-benzopyran-4-one
5,7-dideoxyquercetin
DTXSID40209494
3',4'-dihydroxyflavonol, >=98% (hplc)
FT-0719677
CS-0092576
HY-111804
Q27287663
tert-butyl?5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylcarbamate
EN300-7502956
Z2216891757

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" However, its relatively high EC(50) in cell based assays, low lipophilicity, high topological polar surface area (tPSA), and poor bioavailability suggest that there is room for medicinal chemical improvement."( Chemical modification of the multitarget neuroprotective compound fisetin.
Chiruta, C; Dargusch, R; Maher, P; Schubert, D, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Furthermore, the duration of benefit and the influence of different dosing regimens remain unclear."( Treatment with quercetin and 3',4'-dihydroxyflavonol inhibits platelet function and reduces thrombus formation in vivo.
Jackson, DE; Linden, MD; Mosawy, S; Woodman, OL, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxyflavanA member of the class of flavans in which one or more ring hydrogens are replaced by hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.58490.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency0.12590.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency0.12590.025120.237639.8107AID886
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency10.00000.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency2.23870.125919.1169125.8920AID2549
15-lipoxygenase, partialHomo sapiens (human)Potency1.99530.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency8.06250.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency31.62280.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency19.95260.316212.443531.6228AID902
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency25.11891.000012.232631.6228AID1452
cytochrome P450 2C19 precursorHomo sapiens (human)Potency25.11890.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency31.62280.00636.904339.8107AID883
mitogen-activated protein kinase 1Homo sapiens (human)Potency25.11890.039816.784239.8107AID995
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency31.62280.00798.23321,122.0200AID2551
DNA polymerase kappa isoform 1Homo sapiens (human)Potency0.35480.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency33.49830.058010.694926.6086AID588379
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency12.58930.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency24.00940.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cyclin-dependent kinase 2Homo sapiens (human)IC50 (µMol)4.00000.00041.044410.0000AID298693
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID1166599Agonist activity at human PTH receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166587Agonist activity at mouse MC4 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID612833Cardioprotection activity in ischemia/reperfusion-induced Sprague-Dawley rat hindquarters assessed as reduction in circulating LDH level at 5 mg/kg, bolus dose administered 5 mins prior to reperfusion measured 2 hrs after reperfusion by UV-VIS spectrophot2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Synthesis of a hypoxia-targeted conjugate of the cardioprotective agent 3',4'-dihydroxyflavonol and evaluation of its ability to reduce ischaemia/reperfusion injury.
AID1166596Agonist activity at human A1 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID293299Antioxidant activity in BALB/c mouse BM cells assessed as inhibition of ROS production2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID232853Antioxidant activity was determined using trolox equivalent antioxidant capacity assay.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis of novel 3,7-substituted-2-(3',4'-dihydroxyphenyl)flavones with improved antioxidant activity.
AID319893Vascular activity in KPSS precontracted Sprague-Dawley rat thoracic aorta assessed as endothelium dependent relaxation2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID646591Antiinflammatory activity in mouse N9 cells assessed as reduction of LPS-induced microglial activation at 1 to 10 uM measured as nitrite level after 24 hrs by Griess reagent-based assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID646588Neuroprotective activity in mouse HT22 cells assessed as reduction in IAA-induced ischemia after 24 hrs by MTT assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID612835Cardioprotection activity in ischemia/reperfusion-induced in Sprague-Dawley rat hindquarters assessed as reduction in MPO level at 5 mg/kg, bolus dose administered 5 mins prior to reperfusion by spectrophotometric analysis relative to control2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Synthesis of a hypoxia-targeted conjugate of the cardioprotective agent 3',4'-dihydroxyflavonol and evaluation of its ability to reduce ischaemia/reperfusion injury.
AID319896DPPH scavenging activity in Sprague-Dawley rat thoracic aorta at 100 uM relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID1166591Agonist activity at human orexin 2 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166580Agonist activity at human MC1 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID319895Antioxidant activity in Sprague-Dawley rat thoracic aorta assessed as superoxide levels at 10 uM by NBT assay relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID613131Drug uptake in rat Con8 cells assessed as compound level in supernatant under hypoxic condition at 10'-5 M after 3 hrs by HPLC analysis2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Synthesis of a hypoxia-targeted conjugate of the cardioprotective agent 3',4'-dihydroxyflavonol and evaluation of its ability to reduce ischaemia/reperfusion injury.
AID319901Effect on acetylcholine-induced vasorelaxation in pyrogallol exposed Sprague-Dawley rat thoracic aorta2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID1166583Agonist activity at human MC4 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID502292Antioxidant activity assessed as DDPH radical scavenging activity2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Relationships between structures of hydroxyflavones and their antioxidative effects.
AID646592Antioxidant activity against ABTS radical assessed as trolox equivalent after 4 mins by TEAC assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID319894Antioxidant activity in Sprague-Dawley rat thoracic aorta assessed as superoxide levels at 10 uM by lucigenin-enhanced chemiluminescence assay relative to control2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID319898Vasorelaxant activity against U46619-induced contraction in endothelium-denuded Sprague-Dawley rat thoracic aorta2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID1668637Inhibition of human liver FBP1 at 200 uM incubated for 5 mins by fluorescence method relative to control2020Journal of natural products, 05-22, Volume: 83, Issue:5
Structural Specificity of Flavonoids in the Inhibition of Human Fructose 1,6-Bisphosphatase.
AID646595Induction of Nrf2 expression in mouse HT22 cells from 1 to 4 hrs by immunoblotting2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID1166601Agonist activity at human NPY5 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID646593Ratio of fisetin EC50 to compound EC50 for neuroprotectivie activity in mouse HT22 cells2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID613133Drug uptake in rat Con8 cells assessed as compound level in cell lysate under hypoxic condition at 10'-5 M after 3 hrs by HPLC analysis2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Synthesis of a hypoxia-targeted conjugate of the cardioprotective agent 3',4'-dihydroxyflavonol and evaluation of its ability to reduce ischaemia/reperfusion injury.
AID1166582Agonist activity at human MC3 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166586Agonist activity at mouse MC3 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID319899Vasorelaxant activity against KCl-induced contraction in endothelium-intact Sprague-Dawley rat thoracic aorta2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID319900Vasorelaxant activity against KCl-induced contraction in endothelium-denuded Sprague-Dawley rat thoracic aorta2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID1166590Agonist activity at human 5HT2C receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166588Agonist activity at mouse MC5 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID180466Inhibitory effect on the oxidative degradation of membrane lipids (lipid peroxidation assay) in microsomes of rat.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis of novel 3,7-substituted-2-(3',4'-dihydroxyphenyl)flavones with improved antioxidant activity.
AID1166595Agonist activity at human D5 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID613132Drug uptake in rat Con8 cells assessed as compound level in cell lysate under normoxic condition at 10'-5 M after 3 hrs by HPLC analysis2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Synthesis of a hypoxia-targeted conjugate of the cardioprotective agent 3',4'-dihydroxyflavonol and evaluation of its ability to reduce ischaemia/reperfusion injury.
AID319897Vasorelaxant activity against U46619-induced contraction in endothelium-intact Sprague-Dawley rat thoracic aorta2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID1166592Agonist activity at human MCH1 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166598Agonist activity at human A3 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166593Agonist activity at human M1 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166600Agonist activity at human C5a receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166594Agonist activity at human D1 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166581Agonist activity at human MC2 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID612837Cardioprotection activity in ischemia/reperfusion-induced Sprague-Dawley rat hindquarters assessed as reduction in circulating LDH level at 5 mg/kg, bolus dose administered 5 mins prior to reperfusion measured 3 hrs after reperfusion by UV-VIS spectrophot2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Synthesis of a hypoxia-targeted conjugate of the cardioprotective agent 3',4'-dihydroxyflavonol and evaluation of its ability to reduce ischaemia/reperfusion injury.
AID1166584Agonist activity at mouse MC1 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID319902Effect on acetylcholine-induced vasorelaxation in xanthine/xanthine oxidase exposed Sprague-Dawley rat thoracic aorta2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity.
AID612830Vasorelaxant activity in phenylephrine and KPSS-precontracted Sprague-Dawley rat thoracic aortic rings at 10'-10 to 10'-4 M measured after 20 mins2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Synthesis of a hypoxia-targeted conjugate of the cardioprotective agent 3',4'-dihydroxyflavonol and evaluation of its ability to reduce ischaemia/reperfusion injury.
AID298693Inhibition of CDK22007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
3-Hydroxychromones as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
AID613130Drug uptake in rat Con8 cells assessed as compound level in supernatant under normoxic condition at 10'-5 M after 3 hrs by HPLC analysis2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Synthesis of a hypoxia-targeted conjugate of the cardioprotective agent 3',4'-dihydroxyflavonol and evaluation of its ability to reduce ischaemia/reperfusion injury.
AID1166597Agonist activity at human A2a receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID293297Antioxidant activity assessed as DPPH radical scavenging activity after 20 min2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID1166589Agonist activity at human NMU1 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID613134Vasorelaxant activity in Sprague-Dawley rat thoracic aortic rings assessed as inhibition of phenylephrine-induced contraction at 10'-5 M after 20 mins2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Synthesis of a hypoxia-targeted conjugate of the cardioprotective agent 3',4'-dihydroxyflavonol and evaluation of its ability to reduce ischaemia/reperfusion injury.
AID1166602Agonist activity at human Glu receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID293298Antioxidant activity assessed as inhibition of superoxide production by xanthine/xanthine oxidase method2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
AID1166585Agonist activity at mouse MC2 receptor at 100 uM to 5 mM2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID1166579Agonist activity at human NMU2R transfected in HEK293 cells after 7 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and biological activity of flavonoid derivatives as selective agonists for neuromedin U 2 receptor.
AID646589Neuroprotective activity against glutamate-induced GSH loss in mouse HT22 cells assessed as intracellular GSH level at 1 to 10 uM after 24 hrs2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
AID646590Neurotrophic activity in rat PC12 cells assessed as neurite outgrowth at 1 to 10 uM after 24 hrs2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Chemical modification of the multitarget neuroprotective compound fisetin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (31.43)29.6817
2010's21 (60.00)24.3611
2020's3 (8.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.51 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (97.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]